Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside [Yahoo! Finance]
Pyxis Oncology, Inc. (PYXS)
Company Research
Source: Yahoo! Finance
antibody-drug conjugates (ADCs) with enhanced potency, stability, and tolerability. The analyst points out that Pyxis' lead drug, PYX-201, is an ADC that targets Extradomain-B Fibronectin (EDB+FN) in the tumor stroma and releases a toxic payload into the tumor microenvironment. The analyst has initiated with an Overweight rating with a price target of $13 Stephens notes that the ADC technology has shown strong potential, with recent successes boosting confidence in its market growth. Also Read: Pyxis Oncology M&A Spotlight Signals Potential Growth Amidst Competitive ADC Landscape: Analyst Pyxis has demonstrated that proteases and the acidic conditions of the tumor stroma can break down the payload linker, similar to the process when the drug is absorbed by cells. The company is about to announce results from the first phase of its human clinical trial for PYX-201, which treats various solid tumors. This update, expected this month, could significantly impact the stock pric
Show less
Read more
Impact Snapshot
Event Time:
PYXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PYXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PYXS alerts
High impacting Pyxis Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
PYXS
News
- Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, down previously from $7.00.MarketBeat
- Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $8.00 price target on the stock, down previously from $10.00.MarketBeat
- Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 [Yahoo! Finance]Yahoo! Finance
- Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201GlobeNewswire
- CFO & COO of Pyxis Oncology Pamela Connealy Buys 13% More Shares [Yahoo! Finance]Yahoo! Finance
PYXS
Earnings
- 11/12/24 - Miss
PYXS
Sec Filings
- 12/23/24 - Form SCHEDULE
- 12/23/24 - Form 4
- 12/23/24 - Form 4
- PYXS's page on the SEC website